epiglucan and Immunologic-Deficiency-Syndromes

epiglucan has been researched along with Immunologic-Deficiency-Syndromes* in 3 studies

Reviews

1 review(s) available for epiglucan and Immunologic-Deficiency-Syndromes

ArticleYear
Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients.
    Medecine et maladies infectieuses, 2014, Volume: 44, Issue:5

    Pneumocystis jirovecii is the only fungus of its kind to be pathogenic in humans. It is primarily responsible for pneumonia (PJP). The key to understanding immune defences has focused on T-cells, mainly because of the HIV infection epidemic. Patients presenting with PJP all have a CD4 count below 200/mm(3). The introduction of systematic primary prophylaxis and the use of new anti-retroviral drugs have significantly reduced the incidence of this disease in the HIV-infected population, mainly in developed countries. The increasingly frequent use of corticosteroids, chemotherapy, and other immunosuppressive drugs has led to an outbreak of PJP in patients not infected by HIV. These patients presenting with PJP have more rapid and severe symptoms, sometimes atypical, leading to delay the initiation of a specific anti-infective therapy, sometimes a cause of death. However, the contribution of new diagnostic tools and a better understanding of patients at risk should improve their survival.

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; beta-Glucans; Connective Tissue Diseases; Drug Therapy, Combination; Early Diagnosis; HIV Seronegativity; Humans; Immunocompromised Host; Immunologic Deficiency Syndromes; Immunologic Factors; Immunosuppressive Agents; Neoplasms; Organ Transplantation; Pneumocystis carinii; Pneumocystis Infections; Pneumonia, Pneumocystis; Polymerase Chain Reaction; Postoperative Complications; Prognosis; Radiography; Trimethoprim, Sulfamethoxazole Drug Combination

2014

Other Studies

2 other study(ies) available for epiglucan and Immunologic-Deficiency-Syndromes

ArticleYear
Effect of sulfated yeast beta-glucan on cyclophosphamide-induced immunosuppression in chickens.
    International immunopharmacology, 2019, Volume: 74

    Immunosuppression is a condition that causes large economic losses in the poultry industry. To investigate the effect of sulfated yeast beta-glucan on immunosuppression, two hundred and fifty 11-day-old chickens were randomly assigned to five groups, and except for the normal control group, injected with cyclophosphamide once a day for 3 successive days. At 14 days of age, sulfated yeast beta-glucan from Saccharomyces cerevisiae(sGSC) was orally administered at three doses to the chickens in three experimental groups for 14 days. On days 7 and 14 after the first sGSC dose, serum cytokine concentrations and peripheral lymphocyte proliferation were measured. Gut microbiota, organ index, and histopathological changes in the bursa were investigated on day 14. The results demonstrated that at 4 mg/kg, sGSC could significantly enhance the bursa index and IFN-γ and IL-6 concentrations, decrease TGF-β1 concentration, and promote lymphocyte proliferation; it could effectively decrease histopathological changes in the bursa and improve gut Bifidobacterium and Lactobacillus populations in cecal digesta of chickens compared with the model control group. This indicated that sGSC could effectively alleviate immunosuppression and regulate the beneficial microbiota in the gut.

    Topics: Adjuvants, Immunologic; Animals; Antigens, Fungal; beta-Glucans; Cell Proliferation; Chickens; Cytokines; Gastrointestinal Microbiome; Glucans; Immunologic Deficiency Syndromes; Immunomodulation; Lymphocyte Activation; Lymphocytes; Poultry Diseases; Saccharomyces cerevisiae

2019
The current management landscape: aspergillosis.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:suppl 2

    Diagnosing invasive aspergillosis (IA) has long been challenging due to the inability to culture the causal Aspergillus agent from blood or other body fluids. This shortcoming has fuelled an interest in non-culture-based diagnostic techniques such as the detection of galactomannan (GM) in blood and bronchoalveolar lavage fluid, the detection of 1,3-β-d-glucan (BDG) in blood and the detection of Aspergillus DNA by PCR-based techniques. Past decades have witnessed important improvements in our understanding of the strengths and limitations of antigen assays and in the standardization of PCR-based DNA techniques. These assays are now being incorporated into care pathways and diagnostic algorithms; they help us to steward and monitor antifungal therapies and to predict treatment outcomes.

    Topics: Aspergillus; beta-Glucans; Biomarkers; Bronchoalveolar Lavage Fluid; DNA, Fungal; Galactose; Humans; Immunologic Deficiency Syndromes; Invasive Pulmonary Aspergillosis; Mannans; Polymerase Chain Reaction

2016